Clinical StudiesVogt-Koyanagi-Harada–like Syndrome Complicating Pembrolizumab Treatment for Metastatic MelanomaBricout, Marion*; Petre, Adeline†; Amini-Adle, Mona†; Bezza, Widad*; Seve, Pascal‡; Kodjikian, Laurent§; Dalle, Stéphane†; Thomas, Luc†Author Information Departments of *Ophthalmology †Dermatology, LYON SUD Hospital Center, Hospices Civils of Lyon, Pierre Bénite Cedex Departments of ‡Internal Medicine §Ophthalmology, Croix-Rousse Hospital, Hospices Civils of Lyon, Lyon, France Reprints: Mona Amini-Adle, Department of Dermatology, Lyon 1 University, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon,165 Chemin du Grand Revoyet, 69495 Pierre Bénite Cédex, France. E-mail: email@example.com. Journal of Immunotherapy: February/March 2017 - Volume 40 - Issue 2 - p 77-82 doi: 10.1097/CJI.0000000000000154 Buy Metrics Abstract Vogt-Koyanagi-Harada (VKH) syndrome is a rare condition implicating systemic immune reaction against melanocytes. The pathophysiology is unclear. A genetic predisposition has been suggested as HLA-DR4/DRB1*04 is more common among VKH patients. Drug induced VKH syndrome has been reported in advanced melanoma patients receiving immunotherapy, including ipilimumab and adoptive cell transfer of Tumor-Infiltrating Lymphocyte associated with IL-2. To date, no case of anti PD-1 -induced VKH syndrome has been described. We report here the case of a HLA-DR4/DRB1*04 patient successfully treated with anti PD-1 for advanced melanoma who developed a systemic immune reaction against melanocytes for whom we discuss a VKH-like syndrome diagnosis in a potentially genetically predisposed patient. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.